Richter was the first pharma company in the region to list its shares on the stock market under an IPO in 1994. The privatisation programme was launched, resulting in the gradual reduction of the state-owned share in the company.
1998 Gedeon Richter Romania S.A.
1998 Gedeon Richter Plc buys Armedica in Târgu Mureş from the Romanian state. This company is the predecessor of Gedeon Richter Romania S.A.
1999 Gedeon Richter Rus gyar
1999 Gedeon Richter-Rus begins operation in Russia.
1999 Magyar Kemiaoktatasert Dij
Richter Gedeon Plc established an award in 1999 for chemistry teachers in primary, secondary and post-secondary vocational education to support and enhance the quality of chemistry education in schools. The prize is aimed primarily at the recognition of chemistry teachers in Hungary, but it is also possible to recognise chemistry teachers teaching in Hungarian in schools beyond the national borders.
a felujitott saspatika
In 2000, our Company bought the pharmacy. After the purchase, the Neo-Renaissance colonial-style furniture was restored. The nature of the equipment has not changed over the years, but of course, minor additions and replacements have been made. The symbol of the pharmacy, the eagle with spread wings, still adorns the officina in its original form.
REF 0162 RGK IV atriuma
2000 - RGK IV.
The staff of the product development department set up in 2000 works in a modern environment that meets the requirements of the 21st century. At the end of the 1990s, the largest domestic investment project included special warehouses in the basement, offices and libraries on the ground floor, and laboratories on the upper floors. Development work is being carried out by 4 departments on 5 floors in the building. The building houses the preparation rooms serving the adjoining, fully automated high-bay warehouse (RGK V).
The cariprazine molecule was discovered by Richter researchers in the early 2000s. The research, which lasted for almost a decade and a half, has borne fruit. Our latest original product has been an industrial success story, having reached USD 1 billion a year in turnover since its launch in the US in 2017. Cariprazine is currently the only antipsychotic that has been shown to be effective in treating not only positive symptoms of schizophrenia (e.g. delusions or hallucinations) but also predominant negative symptoms (e.g. emotional blunting, also known as reduced affect display, anhedonia, and loss of drive).
2002 Gedeon Richter Polska
2002 The new member of the Richter Group is the pharmaceutical company GZF Polfa, now Gedeon Richter Polska.
In 2004, a new company was founded in India under the name Richter-Themis Medicare for the purpose of manufacturing active agents. The plant began its operations in 2006. Today, it employs 400 people.
2005 Innovacios nagydij
Lisonorm, a combined antihypertensive drug, was awarded the Innovation Grand Prize in 2005. The Hungarian Innovation Association decided to establish the Innovation Grand Prize in 1991. The Grand Prize, which is awarded once a year, is given to a company registered in Hungary that has implemented a significant innovation in the year preceding the award ceremony and has thus achieved outstanding profit. The bronze statuette symbolising the award –originally entitled ‘Forms bending towards each other’ – was made by Miklós Borsos, a sculptor who was awarded the Munkácsy and Kossuth Prizes. The statuette was offered by the sculptor’s widow for the purposes of the award.
Our Company has won recognition in the competition several times over the years.
Last year, our biosimilar product Terrosa won the Innovation Grand Prize.
Perhaps it is not going too far to say that the ‘crown jewel’ of Richter Gedeon Plc’s architectural programme is also one of the most important Hungarian contemporary buildings of the last decade. Within its genre, the Chemical Research and Office Building, which was commissioned in 2007, is world-class in its aesthetic quality, functional concept, construction and use of materials.
- useful floor space: approximately 19,000 sqm
- number of people working in the building: close to 500 people
- awards (in architecture):
Budapest Architecture Award for Excellence – 2008
Hungarian Real Estate Development Special Award for Excellence 2009
FIABCI International Real Estate Development Award for Excellence 2010
Pro Architectura Award 2011 (designers’ award)
2007 Richter Helm Biologics
2007 In 2007, Richter acquired a family-owned Hamburg-based plant and the associated R&D capacity in Germany and, together with its partner Helm AG, set up a joint venture by acquiring a majority stake. Richter Helm Biologics today operates as a biosimilar plant for producing bacterial and yeast-based products, an experimental pilot plant and a related laboratory.
Health for thousands, millions for the hospital!
Richter Gedeon Plc launched the programme in 2009 to support the preventive activities of local healthcare institutions and to provide them with financial support for necessary improvements. Over the years, Healthy City has become an event that hosts a wide range of health screenings, counselling sessions, sports programmes and interactive motivational presentations.
Richter Innovative Knowledge Fund Award and Archive (RITA)
In 2010, the Company established the Richter Innovative Knowledge Fund Award and Archive (RITA), a competition scheme for Richter employees to recognise innovative teamwork. The competition is open to teams of 3-5 people, who are invited to submit an innovative idea, result, solution, innovation of a primarily practical nature for any of the Company’s activities, which has brought or is likely to bring some commercially valuable benefit to the Company. A key feature of RITA Creation is that it clearly reinforces the Company’s know-how.
debreceni biotechnologiai uzem
Gedeon Richter Plc’s Biotechnology Plant, which plays a key role in Debrecen’s economy, was commissioned in 2012 in the Industrial Park in Határ Street. Thanks to substantial improvements made since then, the division developing and producing biosimilar products was further expanded in 2016, and the Molecular Biology Lab was opened in 2018. With these steps, the total investment in Debrecen has exceeded HUF 40 billion.
2013 Vegyesvallalata letrehozasa Kinaban
Richter establishes another joint venture with Rxmidas Pharmaceuticals Co Ltd in China in 2013.
reagila az ev gyogyszere 2020
Richter’s atypical antipsychotic, Reagila containing the active agent cariprazine was awarded the Medicine of the Year 2019 prize by the Hungarian Society for Experimental and Clinical Pharmacology (MFT). Each year, this prestigious award recognises the most advanced and effective products that have made a significant breakthrough in the treatment of a disease.
Debreceni kozossegi es irodaepulet
The building complex built on a total floor space of 3,500 sqm has 72 new office workstations, a restaurant, a conference hall, meeting rooms equipped with state-of-the-art infocommunication technology, a doctor’s consultation room, facilities for mechanical and electronic systems, as well as a server room.
2020 - Flower Carnival
The Debrecen Flower Carnival dates back more than 50 years. It is one of the best-known events in this large city on the Great Plains, held every year on August 20. In addition to the flower carts decorated with live and dry flowers, the performances of Hungarian and international dance and music groups add colour to the parade. In 2020, Gedeon Richter was also represented at the event with a decorated flower cart.
2020 Innovacios nagydij Terrosa
The jury of the Hungarian Innovation Grand Prize awarded Richter Gedeon Plc the 2020 Hungarian Innovation Grand Prize for Terrosa®, a biosimilar product developed for the treatment of osteoporosis.One of the fastest growing segments of the world’s pharmaceutical markets is the market for biotechnologically produced biosimilar drugs. Biosimilar products provide treatment that is as effective and safe as the original biotechnology drugs, but at the same time much more cost-effective, reducing the financial burden on health insurers and facilitating patient access to that therapy.